Introduction
============

Lung cancer is the leading cause of cancer-associated mortality worldwide, accounting for 1.3 million mortalities annually (World Health Organization, 2008) ([@b1-ol-0-0-8882]). It has the highest mortality rate of all types of cancer in women and men globally, with its mortality rate exceeding the combined mortality rates of breast, prostate, colorectal and pancreatic cancer ([@b1-ol-0-0-8882]). Non-small cell lung cancer (NSCLC) accounts for \~80% of all lung cancer cases globally, with \~75% of patients being diagnosed in the middle-late stages, and the 5-year survival rate of NSCLC is poor (mean, 9--11 months) ([@b2-ol-0-0-8882]). NSCLC includes squamous cell carcinoma, adenocarcinoma and large cell carcinoma subtyes ([@b3-ol-0-0-8882]); and NSCLC cells divide more slowly and spread relatively late compared with small-cell carcinoma cells. At present, the lack of knowledge concerning the molecular mechanisms of NSCLC progression has limited the development of novel treatment strategies. However, in combination with a large number of applications involving bioinformatics available for clinical studies, a large volume of disease-associated bioinformatics data has been produced. Obtaining detailed biological information from these resources is valuable for the study and development of therapeutic strategies for NSCLC.

High-throughput bioinformatics platforms may promote the analysis of differential gene expression, including microarrays, and have a wide range of applications in medical oncology, particularly in searching for disease-associated biomarkers ([@b4-ol-0-0-8882]), alternative splicing ([@b5-ol-0-0-8882]) and gene function prediction ([@b6-ol-0-0-8882]). Numerous previous studies have generated a large volume of microarray data, and a number of gene expression profiling studies on NSCLC have identified differentially expressed genes (DEGs) in various pathways, molecular functions and biological processes.

Therefore, in the present study, the original data (GSE33532) was downloaded from the Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>), which contains variations in gene expression profiles in stage I and II (Tumor-Node-Metastasis classification of malignant tumors) ([@b7-ol-0-0-8882]) NSCLC tissues ([@b8-ol-0-0-8882]), and in normal tissues. The gene expression profiling of NSCLC tissues has resulted in the establishment of several prognostic and predictive gene signatures with little overlap ([@b8-ol-0-0-8882]). Subsequently, R software (version 3.4.1; <https://www.r-project.org/>) was used to compare the expression profiles of NSCLC tissues with those of normal tissues in order to identify DEGs. Subsequent to obtaining the DEGs, biological function enrichment and integrated protein-protein interaction network (PPI) analyses were performed to establish the complete characterization of the DEGS for NSCLC and obtain further understanding into the mechanism underlying NSCLC. By analyzing the biological function of the DEGs, certain potential biomarkers were identified for additional study.

Materials and methods
=====================

### Microarray data

The GSE33532 microarray expression dataset was downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). This dataset was based on the Affymetrix GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array), submitted by Meister *et al* ([@b8-ol-0-0-8882]). The GSE33532 dataset contained 100 samples, including 80 NSCLC tissue samples and 20 normal tissue samples.

### Identification of DEGs

The raw data used for analysis contained CEL files (GPL570 platform), and the results were obtained using Affy package (version 1.52.0) ([@b9-ol-0-0-8882]), Limma package (version 3.0.1) ([@b10-ol-0-0-8882]) and Gplot package (version 3.3.2; <https://cran.r-project.org/web/packages/gplots/>). A hierarchical clustering method was applied to classify these data into either the NSCLC or normal group. The quality control was indicated by using the 'Robust Multiarray Averaging' (RMA) function in the Affy packages. Subsequently, the adjust method 'BH' in the Limma R package was used to identify DEGs with log \|fold change\|\>1 and adj. P\<0.05 as cut-off levels for statistically significant candidate genes. Following this, a heatmap was constructed to indicate the differential expression levels of the top 100 DEGs (50 upregulated and 50 downregulated), and a volcano plot was produced to map all DEGs in this dataset.

### Gene Ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analyses

In the field of molecular biology, GO is the most developed and widely-used ontology. Through the GO method, it is also possible to characterize biological concepts with different specificity levels, from general to precise concepts ([@b11-ol-0-0-8882]). KEGG (<http://www.genome.ad.jp/kegg/>) is a collection of databases and associated software for understanding and simulating higher-order functional behaviors of cells or organisms from their genomic information ([@b12-ol-0-0-8882]). In addition, analyzing DEGs using the Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.ncifcrf.gov/>) is an important means of identifying the relevant biological functions for any high-throughput gene functional analysis ([@b13-ol-0-0-8882]). The DEGs of the present study were analyzed to identify their biological function using the results from the GO and KEGG pathway analyses and the DAVID online tool. P\<0.05 was considered to indicate a statistically significant difference.

### Disease module creation using the integration of PPIs

The Search Tool for the Retrieval of Interacting Genes (STRING) database includes 5,214,234 proteins from 1,133 organisms. It identified the PPIs of the DEGs identified in the present study. To evaluate their interactive associations, all DEGs were mapped to this database, in order to get an improved result, interactions with the highest confidence score (score \>0.9) in the STRING database were selected. Subsequently, the PPIs were analyzed by Cytoscape software (version 3.2.1; National Resource for Network Biology) ([@b14-ol-0-0-8882]) to obtain the PPI network. The criteria of disease module searching were set as follows: Molecular COmplex DEtection (MCODE) score \>3, and each module must have \>4 nodes. P\<0.05 was considered to indicate a statistically significant difference.

### Pathway crosstalk

The regulation of biological pathways is complex, yet it underlies the functional coordination of cells ([@b15-ol-0-0-8882]). Cancer is a disease that is characterized by unregulated cell proliferation, driven by underlying pathway deregulation ([@b16-ol-0-0-8882]). This pathway deregulation occurs within and between pathways ([@b17-ol-0-0-8882]). Pathway crosstalk analysis may assist in identifying the interactions among pathways enriched by DEGs. The present study used the pathway information of DEGs from the KEGG database to conduct a pathway crosstalk analysis in NSCLC. The principle of pathway crosstalk is defined by \>3 overlapping genes in 2 pathways (each pathway must have ≤5 genes) ([@b17-ol-0-0-8882]). To measure the interaction of crosstalk, 2 novel variables were introduced: The Jaccard Coefficient (JC) $\text{JC} = \left| \frac{A \cap B}{A \cup B} \right|$ and the Overlap Coefficient (OC) $\text{OC} = \frac{\left| {A \cap B} \right|}{\min(\left| A \right|,\left| B \right|)}$, where A and B are the lists of genes included in the 2 analyzed pathways. The rank value (RV) was calculated by $\frac{JC + OC}{2}$ ([@b17-ol-0-0-8882]). Subsequently, Cytoscape software was used to map the interaction between pathways and use RV as the interaction type in order to display the weight of the crosstalk.

### Survival analysis

The Kaplan-Meier plotter (KMplot, <http://www.kmplot.com/analysis>) is capable of assessing the effect of 54,675 genes on survival using 10,293 cancer samples. These include 5,143 breast, 1,648 ovarian, 2,437 lung and 1,065 gastric cancer samples, with mean follow-up periods of 69, 40, 49 and 33 months, respectively. The primary purpose of this tool is to conduct meta-analysis-based biomarker assessments ([@b18-ol-0-0-8882]). The top 9 hub genes of disease module in the present study were entered into the KMplot database to examine the association between these genes and the 5-year survival rates of patients.

Results
=======

### Identification of DEGs

The dataset of the present study contained 100 samples; 20 normal tissue samples and 80 NSCLC tissue samples. Each sample from the chip was analyzed by Affy and Limma packages of R software, respectively. Based on the Affy package, using the RMA method to pre-process the dataset, then using the lmFit function of the Limma package to screen differentially expressed genes with P\<0.05 and fold control (Log\|FC\|)\>1 criteria to obtain DEGs from the dataset, a total of 1,795 genes were identified. Of these, 729 were upregulated and 1,066 were downregulated. The Gplots package (R software) was used to obtain the top 50 upregulated and the top 50 downregulated DEGs, and to produce an expression heatmap ([Fig. 1](#f1-ol-0-0-8882){ref-type="fig"}) and a volcano plot of the DEG distribution ([Fig. 2](#f2-ol-0-0-8882){ref-type="fig"}).

### GO enrichment analysis

Enriched GO categories and KEGG pathways were identified by uploading all DEGs to DAVID. The results of the GO analysis indicated that the upregulated DEGs were significantly enriched in 'biological processes' (BP), which included 'cell cycle' and 'nuclear division' ([Table I](#tI-ol-0-0-8882){ref-type="table"}); downregulated DEGs were also significantly enriched in BP, including 'response to wounding', 'anatomical structure morphogenesis' and 'response to stimulus' ([Table I](#tI-ol-0-0-8882){ref-type="table"}). For 'molecular function', the upregulated DEGs were enriched in 'microtubule motor activity', 'protein binding' and 'structural molecule activity', and the downregulated DEGs were enriched in 'calcium ion binding', 'protein binding' and 'growth factor binding' ([Table I](#tI-ol-0-0-8882){ref-type="table"}). Concurrently, the GO 'cell component' analysis also revealed that the upregulated DEGs were significantly enriched in 'chromosome' and 'centromeric region', and that the downregulated DEGs were enriched in 'plasma membrane part', 'extracellular region part' and 'cell periphery' ([Table I](#tI-ol-0-0-8882){ref-type="table"}).

### KEGG pathway analysis

[Table II](#tII-ol-0-0-8882){ref-type="table"} indicates the KEGG analysis result of the most significantly enriched pathways (top 5 upregulated and downregulated) in the DEGs of NSCLC. The upregulated DEGs were significantly enriched in 'cell cycle', 'DNA replication', 'tumor protein 53 (p53) signaling pathway', 'Extracellular matrix (ECM)-receptor interaction' and 'Protein digestion and absorption', while the downregulated DEGs were significantly enriched in 'Complement and coagulation cascades', 'Malaria', 'Cell adhesion molecules (CAMs)', 'Axon guidance' and 'Renin secretion'.

### Integration of PPIs create disease module

All DEGs of NSCLC were loaded into the STRING database, to obtain the PPI data among them, and PPIs with highest interaction score (confidence \>0.9) were selected. Subsequently, Cytoscape was used to identify the 9 hub nodes with the highest degrees, which included aurora kinase B (AURKB), centromere protein A (CENPA), cyclin dependent kinase 1 (CDK1), proliferating cell nuclear antigen (PCNA), BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B), cell division cycle 20 (CDC20), baculoviral Inhibitor of apoptosis (IAP) repeat containing 5 (BIRC5), MAD2 mitotic arrest deficient-like 1 (MAD2L1) and polo like kinase 1 (PLK1). Of these hub genes ([Table III](#tIII-ol-0-0-8882){ref-type="table"}), CDK1 revealed the highest node degree (degree=58). In addition, a total of 684 nodes and 2,134 edges were analyzed using MCODE in Cytoscape software. The top 5 largest size modules were identified, and the functional annotations of the genes within them were isolated ([Fig. 3](#f3-ol-0-0-8882){ref-type="fig"}). KEGG enrichment analysis of these modules demonstrated that the genes in modules 1--5 were primarily associated with 'cell cycle', 'chemokine signaling pathway', 'protein digestion and absorption', 'DNA replication' and 'malaria'.

### Pathway crosstalk

In order to identify the significantly-enriched pathways and to understand the interaction between them, pathway crosstalk analysis among the 26 significant pathways was performed; in total, these pathways contained 41 edges. Based on the crosstalk analysis, the pathways were divided into two major groups, and each of the included pathways shared more crosstalk events than those outside of the pathways identified in the crosstalk analysis and may be associated with similar biological processes ([Fig. 4](#f4-ol-0-0-8882){ref-type="fig"}). One group primarily included metabolism of amino acids tyrosine, phenylalanine, tryptophan and histidine. The other group primarily contained tumor necrosis signaling pathways: CAM; tumor necrosis factor signaling pathway; leukocyte transendothelial migration; malaria and stress reaction (renin secretion, salivary secretion, platelet activation, vascular smooth muscle contraction, extracellular matrix (ECM)-receptor interaction and oocyte meiosis). These pathways had \>4 degrees and high rank-values with other pathways in this crosstalk.

### Survival analysis

To validate the 9 hub genes identified, the KMplot was used to analyze the survival potential of patients with upregulated hub genes. Following the gene upload, 8 genes were available in KMplot database, and there were 1,926 patients as candidates. All the hub genes were upregulated genes, 7 of which were a significantly associated with low survival rates (P\<0.05; [Fig. 5](#f5-ol-0-0-8882){ref-type="fig"}). However, PCNA was upregulated, but did not exhibit a significant association.

Discussion
==========

NSCLC accounts for \~80% of all types of diagnosed lung cancer ([@b19-ol-0-0-8882]). The cause of NSCLC is complex with various factors, including smoking, air pollution and radon exposure ([@b20-ol-0-0-8882]); therefore, understanding the biological mechanisms of NSCLC is important for clinical diagnosis and treatment. As microarrays have a wide range of applications in oncology, including identification of disease-associated biomarkers, alternative splicing and gene function prediction, microarray data were extracted from GSE33532, and 729 upregulated and 1,066 downregulated DEGs between NSCLC and normal samples were identified using bioinformatics analysis. In order to obtain additional analysis of these DEGs, GO and KEGG analyses were performed using DAVID software.

The GO analysis results indicated that the upregulated DEGs were primarily associated with 'cell cycle phase', 'mitotic cell cycle', 'cell cycle process', 'M phase of mitotic cell cycle' and 'nuclear division', while the downregulated DEGs were primarily associated with 'response to wounding', 'anatomical structure morphogenesis', 'response to stimulus', 'response to chemical stimulus' and 'single-multi cellular organism process'. These results are in agreement with those of previously published studies suggesting that irregular and abnormal cell cycles or cell proliferation are closely associated with tumor proliferation and apoptosis ([@b21-ol-0-0-8882]--[@b24-ol-0-0-8882]), and that there is an association between repetitive wounding/stimuli and lung cancer ([@b25-ol-0-0-8882]).

The KEGG pathway analysis result revealed that upregulated DEGs were involved in 'Cell cycle', 'DNA replication', 'p53 signaling pathway', 'ECM-receptor interaction' and 'protein digestion and absorption'. Previous studies have indicated that the p53-independent structure-activity associations of mesogenic compounds are associated with cytotoxic effects ([@b26-ol-0-0-8882],[@b27-ol-0-0-8882]), and that disturbances in the p53 signaling pathway is associated with NSCLC ([@b28-ol-0-0-8882]). According to previous studies, ECM-receptor interactions were involved in cell adhesion ([@b29-ol-0-0-8882]), and it has been revealed that the ECM molecule hyaluronan induced focal adhesion, to signal the cytoskeletal changes required for the elevated cell motility observed in the processes of tumor cell progression, metastasis and invasion ([@b30-ol-0-0-8882]).

Notably, the downregulated DEGs were enriched in disease malaria during the KEGG enrichment analysis, which may suggest that anti-malaria compounds, artemisinin, dihydroartemisinin and artesunate, also have anticancer potential. The antimalarial drug, artemisinin, was previously used in the treatment of lung cancer, and Tong *et al* ([@b31-ol-0-0-8882]) identified that artemisinin inhibited tumor metastasis through Wnt/β-catenin signaling. In addition, a previous study by Ashton *et al* ([@b32-ol-0-0-8882]) suggested that a commonly used anti-malarial drug, atovaquone, effectively increased the oxygen content inside cancer cells, therefore improving the efficiency of radiation treatment. Atovaquone rapidly decreased the oxygen consumption rate by \>80% in a range of cancer cell lines at pharmacological concentrations. In additional experiments, atovaquone killed 90% of cancer cells in an *in vitro* lung cancer tumor model involving radiotherapy ([@b32-ol-0-0-8882]).

By constructing a PPI network with DEGs, the present study identified the top degree hub genes: CDK1, PLK1, AURKB, CDC20, BIRC5, BUB1B, PCNA, CENPA and MAD2L1. CDK1 exhibited the highest degree of connectivity among these hub genes. CDK1, a protein-coding gene, serves a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle and mitotic onset, promoting G2-M transition and regulating G1 progress and G1-S transition via association with multiple interphase cyclins ([@b33-ol-0-0-8882]). CDK1 is an adverse prognostic biomarker of lung adenocarcinoma (LUAD), and increased expression of CDK1 was revealed to be associated with a higher risk of cancer recurrence and poor survival, compared with the normal expression of CDK1 in patients with LUAD ([@b34-ol-0-0-8882]). Danilov *et al* ([@b35-ol-0-0-8882]) also demonstrated that using dinaciclib to inhibit the expression of CDK1 induced anaphase catastrophe in lung cance ([@b35-ol-0-0-8882]). The second hub gene, PLK1, performs several important functions throughout the M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors and the regulation of mitotic exit and cytokinesis ([@b36-ol-0-0-8882]). A previous study demonstrated that PLK1 may promote tumor cell survival by regulating Myc stabilization; inhibitors of PLK1 preferentially induced potent apoptosis level in MYCN-amplified tumor cells from neuroblastoma and small cell lung cancer, and synergistically potentiated the therapeutic efficacies of Bcl-2 antagonists ([@b37-ol-0-0-8882]). AURKB, the third hub gene, encodes a member of the aurora kinase subfamily of serine/threonine kinases, and participates in the regulation of alignment and segregation of chromosomes during mitosis and meiosis ([@b38-ol-0-0-8882]). A previous study has confirmed the antitumor and radiosensitizing activities of daurinol in human lung cancer cells through the inhibition of AURKB ([@b39-ol-0-0-8882]). In addition, CDC20 serves as a regulatory protein interacting with several other proteins at multiple points in the cell cycle ([@b40-ol-0-0-8882]). A previous study suggested that CDC20 is a critical regulator in glioma tumors, initiating cell proliferation and survival ([@b41-ol-0-0-8882]). High levels of CDC20 expression are a key component of the spindle assembly checkpoint; CDC20 has been identified in various malignancies and serves a vital role in tumorigenesis and progression ([@b42-ol-0-0-8882]--[@b44-ol-0-0-8882]). BIRC5, the member of the IAP gene family, encodes negative regulatory proteins that prevent apoptotic cell death. Han *et al* ([@b45-ol-0-0-8882]) suggested that the upregulation of the anti-apoptosis gene BIRC5 will lead to the inhibition of p53 signaling in H1650GR cells. BUB1B serves a role in the inhibition of the APC/C, delaying the onset of anaphase and ensuring proper chromosome segregation ([@b46-ol-0-0-8882]). Chen *et al* ([@b47-ol-0-0-8882]) also revealed that BUB1B may serve as target gene in lung carcinoma as a result of PPI network analysis. In addition, high levels of BUB1B expression are associated with disease progression and poor survival in patients with lung adenocarcinoma ([@b47-ol-0-0-8882]). PCNA acts as a homotrimer and assists in increasing the processivity of leading strand synthesis during DNA replication ([@b48-ol-0-0-8882]). Bodduluru *et al* ([@b49-ol-0-0-8882]) revealed that benzo\[a\]pyrene may induce pulmonary carcinogenesis by modulating PCNA expression. CENPA encodes a centromere protein that contains a histone H3-associated histone fold domain required for targeting to the centromere ([@b50-ol-0-0-8882]). This domain is one of the basic components of the human active kinetochore, which serves an important role in cell-cycle regulation, cell survival and genetic stability ([@b51-ol-0-0-8882]). Toh *et al* ([@b52-ol-0-0-8882]) identified that CENPA may be considered as a prospective diagnostic and prognostic biomarker of lung adenocarcinoma. MAD2L1 is a component of the mitotic spindle assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate ([@b53-ol-0-0-8882]). As aforementioned, MAD2L1 is closely associated with the carcinogenesis of lung adenocarcinoma ([@b34-ol-0-0-8882]). Guo *et al* ([@b54-ol-0-0-8882]) performed a case-control analysis, indicating an association between the concentration of MAD2L1 Leu84Met SNP gene product and the risk of lung cancer in an allele dose-dependent manner, with the result demonstrating that the expression level of MAD2L1 Leu84Met SNP was linearly associated with the risk of lung cancer.

Considering the enrichment results of the top 5 modules from the PPI network genes in the present study, it was demonstrated that NSCLC was associated with 'cell cycle', 'chemokine signaling pathway', 'protein digestion and absorption', 'DNA replication' and 'malaria'.

In the chemokine signaling pathway (hsa04062; KEGG database), chemokines are a type of small chemoattractant peptide, which may provide directional cues for cell trafficking; this is the key for the protective host response ([@b55-ol-0-0-8882]). In addition, chemokines regulate a plethora of biological processes in hematopoietic cells that lead to cellular activation, differentiation and survival ([@b55-ol-0-0-8882],[@b56-ol-0-0-8882]). A previous study has revealed that chemokines are vital in the pathogenesis of NSCLC and NSCLC cells are rich in the secreted protein CXCL12 ([@b57-ol-0-0-8882]). Another study has suggested that the methylation of CXCL12 has a marked correlation with NSCLC prognosis ([@b58-ol-0-0-8882]), and that CXCL12-mediated adhesion and survival signals are associated with chemo-resistance in lung cancer ([@b59-ol-0-0-8882]).

During the survival analysis of the present study, KMplot was used to assess the effect of high expression levels of the hub genes in patients with lung cancer. There were 8 genes available in the database, with only CDK1 not matching HGU133A and HGU133Aplus2 probe set IDs in the KMplot database. Notably, 7 of the 8 genes indicated significantly low survival rates, compared with low expression samples (P\<0.05); the remaining gene, PCNA, did not. In addition, a number of previous studies have analyzed the association between the expression of PCNA and NSCLC postoperative survival time and did not identify a significant correlation ([@b60-ol-0-0-8882]--[@b63-ol-0-0-8882]). This may be due to the fact that the prognosis of lung cancer may be affected by a variety of factors, including pathological type and stage, differentiation, treatment, complications, age, physical condition and the expression of PCNA ([@b60-ol-0-0-8882],[@b64-ol-0-0-8882]--[@b67-ol-0-0-8882]). It is difficult to predict the prognosis of lung cancer by considering the effecters of PCNA alone.

In conclusion, the results from the present study provided a wider analysis of the DEGs associated with NSCLC, and identified certain key pathways in the progress of NSCLC, which may provide guidance for future studies. Nevertheless, a number of biomarkers associated with NSCLC remain uncharacterized; additional biological and bioinformatics analyses are required.
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###### 

Gene Ontology analysis of DEGs associated with non-small cell lung cancer.

  A, Upregulated DEGs                                                                                           
  --------------------------- ---------------------------------------------------------------- ---------------- --------------
  BP                          GO:0022403; cell cycle phase                                     117              3.56×10^−30^
  BP                          GO:0000278; mitotic cell cycle                                   106              3.67×10^−27^
  BP                          GO:0022402; cell cycle process                                   124              3.65×10^−26^
  BP                          GO:0000087; M phase of mitotic cell cycle                        71               4.22×10^−26^
  BP                          GO:0000280; nuclear division                                     69               1.79×10^−25^
  MF                          GO:0003777; microtubule motor activity                           13               4.16×10^−6^
  MF                          GO:0005515; protein binding                                      323              1.48×10^−5^
  MF                          GO:0005198; structural molecule activity                         45               1.59×10^−5^
  MF                          GO:0016538; cyclin-dependent protein kinase regulator activity   6                4.69×10^−5^
  MF                          GO:0003678; DNA helicase activity                                8                2.00×10^−4^
  CC                          GO:0044427; chromosomal part                                     64               2.90×10^−17^
  CC                          GO:0005694; chromosome                                           70               5.28×10^−17^
  CC                          GO:0000793; condensed chromosome                                 34               2.21×10^−16^
  CC                          O:0000775; chromosome, centromeric region                        32               2.73×10^−16^
  CC                          GO:0000779; condensed chromosome, centromeric region             25               5.44×10^−16^
                                                                                                                
  **B, Downregulated DEGs**                                                                                     
                                                                                                                
  **Category**                **Term/gene function**                                           **Gene count**   **P-value**
                                                                                                                
  BP                          GO:0009611; response to wounding                                 130              1.29×10^−18^
  BP                          GO:0009653; anatomical structure morphogenesis                   198              1.74×10^−18^
  BP                          GO:0050896; response to stimulus                                 468              3.25×10^−18^
  BP                          GO:0042221; response to chemical stimulus                        239              5.30×10^−17^
  BP                          GO:0044707; single-multicellular organism process                406              2.16×10^−16^
  MF                          GO:0005509; calcium ion binding                                  65               1.64×10^−7^
  MF                          GO:0005515; protein binding                                      434              2.35×10^−7^
  MF                          GO:0019838; growth factor binding                                20               2.36×10^−7^
  MF                          GO:0005102; receptor binding                                     99               5.28×10^−7^
  MF                          GO:0097367; carbohydrate derivative binding                      27               7.64×10^−7^
  CC                          GO:0044459; plasma membrane part                                 200              2.10×10^−24^
  CC                          GO:0044421; extracellular region part                            139              2.28×10^−24^
  CC                          GO:0071944; cell periphery                                       346              2.98×10^−21^
  CC                          GO:0005886; plasma membrane                                      338              2.20×10^−20^
  CC                          GO:0005615; extracellular space                                  105              1.81×10^−17^

DEGs, differentially expressed genes; BP, biological process; MF, molecular function; CC, cellular component.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway analysis of DEGs associated with non-small cell lung cancer.

  A, Upregulated DEGs                                                                               
  --------------------------- ------------------------------------------- ----------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa04110                    Cell cycle                                  25          8.4×10^−11^   CDK1, CDC6, E2F3, DBF4, TTK, ESPL1, CDC20, CHEK1, MCM2, PTTG1, SFN, MCM4, CCNB1, CCNE2, CCNE1, CDC45, CDKN2A, CCNB2, MAD2L1, PLK1, PCNA, BUB1B, ORC6, ORC1, CCNA2
  hsa03030                    DNA replication                             10          8.8×10^−6^    PRIM1, DNA2, RFC4, POLE2, PCNA, MCM2, RNASEH2A, MCM4, FEN1, RPA3
  hsa04115                    p53 signaling pathway                       13          1.2×10^−5^    CDK1, CHEK1, SFN, PMAIP1, GTSE1, CCNB1, CCNE2, CCNE1, CDKN2A, CCNB2, SERPINB5, RRM2, IGFBP3
  hsa04512                    Extracellular matrix-receptor interaction   11          2.0×10^−3^    IBSP, COMP, COL3A1, COL1A2, COL1A1, COL11A1, THBS2, COL5A2, COL5A1, SPP1, HMMR
  hsa04974                    Protein digestion and absorption            11          3.0×10^−3^    KCNN4, COL17A1, COL7A1, PRSS2, COL3A1, COL1A2, COL1A1, COL11A1, COL5A2, COL5A1, COL10A1
                                                                                                    
  **B, Downregulated DEGs**                                                                         
                                                                                                    
  **Pathway ID**              **Name**                                    **Count**   **P-value**   **Genes**
                                                                                                    
  hsa04610                    Complement and coagulation cascades         16          4.2×10^−6^    C7, C5AR1, C6, F8, SERPING1, C4BPA, C1QA, C8B, C1QB, VWF, CD55, THBD, SERPIND1, CFD, CPB2, PROS1
  hsa05144                    Malaria                                     12          5.9×10^−5^    CSF3, GYPC, ICAM1, ITGAL, SELP, IL6, CD36, PECAM1, ACKR1, TLR4, HBB, SELE
  hsa04514                    Cell adhesion molecules                     20          3.1×10^−4^    ICAM1, ITGAL, SELP, CLDN18, OCLN, PTPRM, CADM1, ICAM2, CLDN5, NECTIN3, HLA-DMA, CDH5, SIGLEC1, CD34, ITGA8, PECAM1, ESAM, JAM2, SELE, NEGR1
  hsa04360                    Axon guidance                               18          6.3×10^−4^    ABLIM1, PLXNA2, ABLIM3, EFNB2, NTN4, DPYSL2, CXCL12, SLIT2, SLIT3, SEMA5A, SEMA6A, RND1, SEMA6D, FYN, SEMA3G, CFL2, SEMA3E, ROBO2
  hsa04924                    Renin secretion                             12          7.1×10^−4^    AGTR1, ACE, ADRB2, ADRB1, PLCB4, PTGER4, GUCY1A2, GUCY1A3, NPR1, AQP1, CACNA1D, ITPR1

p53, tumor protein 53; DEGs, differentially expressed genes.

###### 

Hub genes and rank of degrees^[a](#tfn3-ol-0-0-8882){ref-type="table-fn"}^.

  Gene symbol   Full name                                                Degree
  ------------- -------------------------------------------------------- --------
  CDK1          Cyclin dependent kinase 1                                58
  PLK1          Polo-like kinase 1                                       53
  AURKB         Aurora kinase B                                          46
  CDC20         Cell division cycle 20                                   42
  BIRC5         Baculoviral initiator of apoptosis repeat containing 5   37
  BUB1B         BUB1 mitotic checkpoint serine/threonine kinase B        36
  PCNA          Proliferating cell nuclear antigen                       35
  CENPA         Centromere protein A                                     34
  MAD2L1        MAD2 mitotic arrest deficient-like 1                     33

Degree, number of interactions connected to a gene.

[^1]: Contributed equally
